Clin Immunol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

1 Abstract The devastating Ebola outbreak in West Africa in 2013-2016 accelerated the progress of several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several IPs were used during that outbreak, but no conclusion on efficacy could be drawn. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs (Remdesivir, Regeneron, ZMapp and MAb114) have been evaluated in a RCT, the Pamoja Tulinde Maisha (PALM) study. Two products (Regeneron and MAb114) demonstrated efficacy as compared to the control arm, ZMapp. Very few side effects have been reported. Results from this scientifically sound study led the FDA to license both products, representing a milestone in EVD therapeutic field. These products can be produced relatively inexpensively and can be stockpiled. The administration of mAbs on EVD patients appears

Democratic republic of the congoDemocratic republic of the generalBas congoVirion glycoproteinsNat microbiolRidgeback biotherapeuticsIan crozierTshiani mbayaProprotein convertase furinRegional office for africaDevelopment of clinicalIi writing groupLeidos biomedical researchMinistry of healthWorld health organizationDevelopment of pan filoviruses